The association of body mass index and prostate-specific antigen in a population-based study

Cancer

Volumn 103, Issue 5, 2005, Pages 1092-1095

  Baillargeon, Jacques ^a,b   Pollock, Brad H ^a   Kristal, Alan R ^c   Bradshaw, Patrick ^a,b   Hernandez, Javier ^a   Basler, Joseph ^a   Higgins, Betsy ^a   Lynch, Steve ^d   Rozanski, Thomas ^e   Troyer, Dean ^b   Thompson, Ian ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d WILFORD HALL MEDICAL CENTER   (United States)

^e BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

Body mass index; Cancer risk; Prostate carcinoma; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; BODY MASS; CANCER STAGING; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ETHNIC GROUP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CARCINOMA; RACE DIFFERENCE; RISK ASSESSMENT; SCREENING TEST; SURVIVAL RATE;

ADULT; AGED; BODY MASS INDEX; HUMANS; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 13944272257     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20856     Document Type: Article

References (18)

1. National Institutes of Health (NIH)/National Heart Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity: the evidence report. Washington, DC: U.S. Government Press, 1998.
2. Allison D, Fontaine K, Manson I, Stevens J, Vanltallie T. Annual deaths attributable to obesity in the United States. JAMA. 1999;282:1530-1538.
3. Putnam S, Cerhan J, Parker A. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000;10:361-369.
4. Schuurman A, Goldbohm R, Dorant E, van den Bradt P. Anthropometry in relation to prostate cancer risk in the Netherlands cohort study. Am J Epidemiol. 2000;151:541-549.
5. Amling C, Kane C, Riffenburgh R. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001;58:723-728.
6. Freedland S, Aronson W, Kane C, et al. Impact of obesity on biochemical control afer radical prostatectomy for clinically localized prostate cancer: a report by the shared equal access regional cancer hospital database study group. J Clin Oncol. 2004;22:446-453.
7. Rohrmann S, Roberts W, Walsh P, Platz E. Family history of prostate cancer and obesity in relation to high-grade disease and extraprostatic extension in young men with prostate cancer. Prostate. 2003;55:140-146.
8. Kolonel L, Yoshizawa C, Hankin J. Diet and prostate cancer: a case-control study in Hawaii. Am J Epidemiol. 1988;127: 999-1012.
9. Ross R, Shimizu H, Paganini-Hill A, Honda G, Henderson B. Case-control studies of prostate cancer in blacks and whites in Southern California. J Natl Cancer Inst. 1987;78: 869-874.
10. Whittemore A, Kolonel L, Wu A, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87:652-661.
11. Wolk A, Moantzoros C, Anderson S, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based case-control study. J Natl Cancer Inst. 1998;90:911-915.
12. Yip I, Herber D, Aronson W. Nutrition and prostate cancer. Urol Clin North Am. 1999;26:403-411.
13. Ku J, Kim M, Lee N, Park Y, Ahn J. Influence of age, anthropometry, and hepatic and renal function on serum prostate-specific antigen levels in healthy middle-age men. Adult Urol. 2003;61:132-136.
14. World Health Organization. Physical status: the use and interpretation of anthropometry: a report of a WHO expert committee. Geneva: World Health Organization, 1995.
15. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < 4.0 ng/ml. N Engl J Med. 2004;350:2239-2246.
16. Riegman PH, Vlietstra RJ, Van der Korput JA, Brinkmann AO, Trapman J. The promoter of prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991;5:1921-1930.
17. Muller M, den Tonkelaar I, Thijssen J, Grobbee D, van der Schous Y. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinol. 2003;149:583-589.
18. Amling C, Riffenburgh R, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.